Benitec Biopharma Inc.
For the period ended Jun 30, 2025. Filed Sep 22, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Sep 22, 2025
BNTC$9.28-6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| Year EndedJune 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(37,917) | $(21,751) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 66 | 87 |
| Amortization of right-of-use assets | 330 | 256 |
| Unrealized loss on investment | — | 1 |
| Gain on extinguishment of liabilities | (764) | — |
| Share-based compensation expense | 17,426 | 830 |
| Changes in operating assets and liabilities: | ||
| Trade and other receivables | 197 | (176) |
| Prepaid and other assets | (111) | 645 |
| Trade and other payables | (2,378) | 941 |
| Accrued employee benefits | (81) | 39 |
| Lease liabilities | (356) | (275) |
| Net cash used in operating activities | (23,588) | (19,403) |
| Cash flows from investing activities: | ||
| Purchase of property and equipment | (18) | (179) |
| Net cash used in investing activities | (18) | (179) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, pre-funded warrants, and common warrants | 30,460 | 70,883 |
| Proceeds from exercise of pre-funded warrants, Series 2 warrants common warrants | 42,344 | 3,038 |
| Share and pre-funded warrants issuance transaction costs | (2,319) | (5,892) |
| Net cash provided by financing activities | 70,485 | 68,029 |
| Effects of exchange rate changes on cash, cash equivalents, and restricted cash | 49 | (8) |
| Net increase in cash, cash equivalents, and restricted cash | 46,928 | 48,439 |
| Cash, cash equivalents, and restricted cash, beginning of period | 50,929 | 2,490 |
| Cash, cash equivalents, and restricted cash, end of period | $97,857 | $50,929 |
| Supplemental disclosure of cash flow information | ||
| Initial measurement of operating lease right-of-use assets and liabilities | $255 | $— |
| Re-measurement of operating lease right-of-use assets and liabilities | $666 | $— |
| Deemed dividend | $— | $619 |
F-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.